Clinical Trials Sponsored by NGM Biopharmaceuticals, Inc

Total 135 results

NGM Biopharmaceuticals, Inc

Completed

A Study of NGM621 in Participants With Geographic Atrophy (CATALINA)

Geographic Atrophy

United States
NGM Biopharmaceuticals, Inc

Completed

Study of NGM621 in Participants With Geographic Atrophy

Geographic Atrophy

United States
NGM Biopharmaceuticals, Inc

Completed

Study of Aldafermin (NGM282) in Participants With Impaired Renal Function

Impaired Renal Function

United States
NGM Biopharmaceuticals, Inc

Completed

Phase 1 SAD and MAD Study of NGM282 in Healthy Adult Participants

Diabetes Mellitus

Australia
NGM Biopharmaceuticals, Inc

Completed

Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function

Impaired Hepatic Function

United States
NGM Biopharmaceuticals, Inc

Completed

Study of NGM395 in Adult Participants

Obesity | NAFLD

Australia
NGM Biopharmaceuticals, Inc

Completed

Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects

Cachexia

Australia
NGM Biopharmaceuticals, Inc

Completed

Study of NGM313 in Obese Participants

Obese

United States
NGM Biopharmaceuticals, Inc

Completed

Phase 1 Study of NGM313 in Healthy Adult Participants

Obesity

Australia
NGM Biopharmaceuticals, Inc

Completed

Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)

Nonalcoholic Steatohepatitis | Compensated Cirrhosis

United States, Australia, Belgium, France, Germany, Hong Kong, Poland, Puerto Rico, United Kingdom
NGM Biopharmaceuticals, Inc

Active, not recruiting

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

Melanoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Bladder Cancer | Non-small Cell Lung Cancer | Metastatic Castration-resistant Prostate Cancer | Head Neck Squamous Cell Carcinoma

United States
NGM Biopharmaceuticals, Inc

Terminated

A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19

SARS-CoV-2 Infection

Australia
NGM Biopharmaceuticals, Inc

Completed

Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese Subjects

Healthy Male

United States
NGM Biopharmaceuticals, Inc

Completed

Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)

NASH - Nonalcoholic Steatohepatitis

United States, Puerto Rico
NGM Biopharmaceuticals, Inc

Completed

Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis

Primary Sclerosing Cholangitis

United States, France, Netherlands, United Kingdom
NGM Biopharmaceuticals, Inc

Completed

Study of NGM282 in Subjects With Functional Constipation and Healthy Individuals

Functional Constipation

United States
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States, Australia, Puerto Rico
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States, Australia, New Zealand
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Phase 2 Study of NGM282 in Patients With Type 2 Diabetes

Diabetes Mellitus

Australia, New Zealand
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States, Australia
NGM Biopharmaceuticals, Inc
Merck Sharp & Dohme LLC

Recruiting

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Breast Cancer | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Non-small Cell Lung Cancer | Colorectal Carcinoma | Bladder Urothelial Cancer | Endocervical...

United States
NGM Biopharmaceuticals, Inc
Merck Sharp & Dohme LLC

Active, not recruiting

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Breast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Non Small Cell Lung Cancer | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Bladder Urothelial Cancer | Endocervical...

United States
NGM Biopharmaceuticals, Inc
Merck Sharp & Dohme LLC

Recruiting

Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Breast Cancer | Glioblastoma | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Pancreatic Ductal Adenocarcinoma | Endocervical Cancer

United States, Korea, Republic of, Taiwan
Michael Camilleri, MD
NGM Biopharmaceuticals, Inc

Completed

Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)

Irritable Bowel Syndrome With Diarrhea | Bile Acid Malabsorption | Chronic Diarrhea | Functional Diarrhea | Bile Acid Diarrhea | Bile Acid Malabsorption Syndrome Type II

United States
Alder Biopharmaceuticals, Inc.

Completed

An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine (PREVAIL)

Migraine Disorder

United States
RegeneRx Biopharmaceuticals, Inc.

Withdrawn

A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers

Myocardial Infarction | Myocardial Ischemia

United States
AgoneX Biopharmaceuticals, Inc.

Not yet recruiting

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous AGX-201 for Migraine Prophylaxis

Migraine Prophylaxis
Alder Biopharmaceuticals, Inc.

Completed

Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine (PROMISE 2)

Migraine Disorders

United States, Belgium, Italy, Spain, United Kingdom, Germany, Hungary, Georgia, Slovakia, Russian Federation, Ukraine, Denmark, Czechia
Alder Biopharmaceuticals, Inc.

Completed

A Multicenter Assessment of ALD403 in Chronic Migraine

Migraine Disorders

United States, Georgia, Australia, New Zealand
RegeneRx Biopharmaceuticals, Inc.

Terminated

A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa

Epidermolysis Bullosa
Alder Biopharmaceuticals, Inc.

Completed

Safety Tolerability and Pharmacokinetics of ALD403

Migraine Disorders

Australia
Gracell Biopharmaceuticals, Inc.

Recruiting

A Study of GC012F, a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma

Relapsed/ Refractory Multiple Myeloma

United States
RegeneRx Biopharmaceuticals, Inc.

Withdrawn

A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction

ST Elevation Myocardial Infarction | Acute Myocardial Infarction | STEMI
Alder Biopharmaceuticals, Inc.

Completed

A Multicenter Assessment of ALD403 in Frequent Episodic Migraine (PROMISE 1)

Migraine Disorders

United States, Georgia
Alder Biopharmaceuticals, Inc.

Completed

Safety, Efficacy and Pharmacokinetics of ALD403

Migraine

United States
RegeneRx Biopharmaceuticals, Inc.

Completed

Study of Thymosin Beta 4 in Patients With Pressure Ulcers

Pressure Ulcers

United States
Paradigm Biopharmaceuticals USA (INC)

Active, not recruiting

Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain

Osteoarthritis, Knee

Australia, United States
Paradigm Biopharmaceuticals USA (INC)

Active, not recruiting

An Observational Follow-up Study to Evaluate Duration of Treatment Effect of Pentosan Polysulfate Sodium in Participants With Knee Osteoarthritis Pain

Osteoarthritis, Knee

United States, Australia
Asklepios Biopharmaceutical, Inc.

Recruiting

NAN-101 in Patients With Class III Heart Failure (NAN-CS101)

Cardiovascular Diseases | Heart Failure | Heart Failure, Diastolic | Congestive Heart Failure | Heart Failure, Systolic | Heart Disease, Ischemic | Heart Failure，Congestive | Heart Arrhythmia | Heart; Complications

United States
Asklepios Biopharmaceutical, Inc.

Recruiting

Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy

Parkinson's Disease | Multiple System Atrophy | Multiple System Atrophy, Parkinson Variant

United States, Poland
Asklepios Biopharmaceutical, Inc.

Recruiting

Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure (GenePHIT)

Congestive Heart Failure

United States
Asklepios Biopharmaceutical, Inc.

Recruiting

A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)

Muscular Dystrophy | Limb Girdle Muscular Dystrophy | LGMD2I | LGMD | Limb-Girdle Muscular Dystrophy Type 2 | LGMD2 | FKRP | FKRP Mutation | Fukutin Related Protein

United States
Asklepios Biopharmaceutical, Inc.

Active, not recruiting

AAV2/8-LSPhGAA (ACTUS-101) in Late-Onset Pompe Disease

Pompe Disease

United States
IGM Biosciences, Inc.

Active, not recruiting

Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer

Solid Tumor

United States
IGM Biosciences, Inc.

Terminated

Evaluation of IGM-6268 in Healthy Adults and Patients With Mild to Moderate COVID-19

COVID-19 | Healthy Volunteers

South Africa
IGM Biosciences, Inc.

Recruiting

A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis

Arthritis | Arthritis, Rheumatoid | Rheumatoid Arthritis

United States, Poland
IGM Biosciences, Inc.

Recruiting

Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States
IGM Biosciences, Inc.

No longer available

Expanded Access of Imvotamab (IGM-2323) in Patients With R/R NHL

Relapsed/Refractory Non-Hodgkin Lymphomas

Australia, Korea, Republic of, Spain
IGM Biosciences, Inc.

Recruiting

A Study of Imvotamab in Severe Systemic Lupus Erythematosus

Systemic Lupus Erythematosus | Lupus Erythematosus

United States, Korea, Republic of, Poland
IGM Biosciences, Inc.

Recruiting

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers

Sarcoma | Acute Myeloid Leukemia | Colorectal Cancer | Solid Tumor | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Chondrosarcoma | Small Lymphocytic Lymphoma

United States, Korea, Republic of, France, Spain, Australia

Clinical Trials Sponsored by NGM Biopharmaceuticals, Inc

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Greece

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations